Skip to main content
SpringerLink
Log in

NMDA-Agonist bremst Dyskinesien auch in der Langzeittherapie

Levodopa-induzierte Dyskinesien bei Morbus Parkinson

  • journal club
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Ory-Magne F, Corvol JC, Azulay JP et al. With drawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial. Neurology 2014; 82: 300–307

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH), Deutschland

    Steffen Paschen

Authors
  1. Steffen Paschen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steffen Paschen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paschen, S. NMDA-Agonist bremst Dyskinesien auch in der Langzeittherapie. InFo Neurologie 16, 30 (2014). https://doi.org/10.1007/s15005-014-0759-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-014-0759-9

Search

Navigation